Renaissance Technologies LLC grew its position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report) by 87.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 438,200 shares of the company’s stock after acquiring an additional 204,100 shares during the period. Renaissance Technologies LLC owned about 0.84% of ALX Oncology worth $2,642,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in ALXO. Vestal Point Capital LP bought a new position in ALX Oncology in the 4th quarter valued at approximately $24,643,000. Redmile Group LLC lifted its holdings in shares of ALX Oncology by 18.2% during the 1st quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock valued at $48,241,000 after buying an additional 667,245 shares during the period. Privium Fund Management B.V. purchased a new stake in shares of ALX Oncology in the 2nd quarter worth $2,271,000. TD Asset Management Inc purchased a new position in shares of ALX Oncology during the 4th quarter valued at about $1,048,000. Finally, Vanguard Group Inc. grew its stake in shares of ALX Oncology by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after acquiring an additional 64,055 shares during the period. 97.97% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $7.90, for a total transaction of $158,000.00. Following the completion of the sale, the insider now owns 593,447 shares of the company’s stock, valued at $4,688,231.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 23,752 shares of company stock valued at $173,003 over the last quarter. 33.40% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Stock Report on ALXO
ALX Oncology Stock Performance
Shares of ALX Oncology stock opened at $1.86 on Wednesday. The stock’s fifty day moving average price is $2.72 and its 200-day moving average price is $8.15. ALX Oncology Holdings Inc. has a 12 month low of $1.76 and a 12 month high of $17.83. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06. The firm has a market cap of $96.91 million, a P/E ratio of -0.50 and a beta of 1.01.
ALX Oncology (NASDAQ:ALXO – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.01. On average, equities research analysts expect that ALX Oncology Holdings Inc. will post -3.04 earnings per share for the current fiscal year.
About ALX Oncology
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
Further Reading
- Five stocks we like better than ALX Oncology
- Why Are Stock Sectors Important to Successful Investing?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Learn Technical Analysis Skills to Master the Stock Market
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What are earnings reports?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.